Glaukos CorporationNYSE: GKOS

Glaukos Announces Participation in Upcoming Investor Conferences

· Issued by Glaukos Corporation via Business Wire

Summary by 6ix AI

Glaukos Corporation, an eye-care pharmaceutical and medical technology company, said its management is scheduled to participate in four investor conferences between November 10, 2026 and December 2, 2026.

Key details

  • Stifel Healthcare Conference on Tuesday, November 10, 2026, at 8:40 a.m. ET in New York City, NY.
  • Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT in London, UK.
  • Piper Sandler Annual Healthcare Conference on Tuesday, December 1, 2026, at 1:30 p.m. ET in New York City, NY.
  • Citi Global Healthcare Conference on Wednesday, December 2, 2026, at 3:00 p.m. ET in Miami, FL.
  • A live and archived webcast will be available, where applicable, in the Investors section of the Glaukos website.

6ix AI wrote this summary from the release below and checked it against the release.

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:

  • Stifel Healthcare Conference on Tuesday, November 10, 2026, at 8:40 a.m. ET in New York City, NY
  • Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT in London, UK
  • Piper Sandler Annual Healthcare Conference on Tuesday, December 1, 2026, at 1:30 p.m. ET in New York City, NY
  • Citi Global Healthcare Conference on Wednesday, December 2, 2026, at 3:00 p.m. ET in Miami, FL

A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

View original source (Business Wire)Glaukos Corporation on 6ix

In the deck

Story so far

Earlier from Glaukos

All Glaukos news releases